Top

Published in:

01-03-2022 | COVID-19 Vaccination | Letter to the Editor

Optimization of FDG PET study after mRNA COVID-19 vaccination to reduce the interference of vaccine-associated hypermetabolic lymphadenopathy

Author: Wajana Thaweerat

Published in: Annals of Nuclear Medicine | Issue 3/2022

Excerpt

Messenger RNA (mRNA) COVID-19 vaccine is one of the main vaccine types currently used for preventing SARS-CoV-2 infection worldwide. However, its administration can interfere with an FDG PET study since an increased uptake of 18F-FDG can be observed at the vaccine injection site and adjacent regional lymph nodes. The interpretation of PET study in oncologic patients might be impacted especially in head and neck cancer, breast cancer or lymphoma in which supraclavicular and axillary lymph node metastases are suspected. Hence, Advani et al. [1] suggest that FDG PET study should be performed at least 2 weeks after vaccination to reduce the interference of lymphadenopathy causing by vaccination in PET interpretation. …

Advani P, Chumsri S, Pai T, Li Z, Sharma A, Parent E. Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients. Ann Nucl Med. 2021;35(11):1264–9. https://doi.org/10.1007/s12149-021-01675-8.CrossRefPubMedPubMedCentral

Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging. 2021;48(6):1854–63. https://doi.org/10.1007/s00259-021-05314-2.CrossRefPubMedPubMedCentral

Eshet Y, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Eifer M. Prevalence of increased FDG PET/CT axillary lymph node uptake beyond 6 weeks after mRNA COVID-19 vaccination. Radiology. 2021;300(3):E345–7. https://doi.org/10.1148/radiol.2021210886.CrossRefPubMed

Cohen D, Hazut Krauthammer S, Wolf I, Even-Sapir E. A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third COVID-19 vaccine dose is short in duration and uncommonly interferes with the interpretation of [18F]FDG PET-CT studies performed in oncologic patients. Eur J Nucl Med Mol Imaging. 2021;15:1–7. https://doi.org/10.1007/s00259-021-05579-7.CrossRef

Becker AS, Perez-Johnston R, Chikarmane SA, Chen MM, El Homsi M, Feigin KN, Gallagher KM, Hanna EY, Hicks M, Ilica AT, Mayer EL, Shinagare AB, Yeh R, Mayerhoefer ME, Hricak H, Vargas HA. Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: radiology scientific expert panel. Radiology. 2021;300(2):E323–7. https://doi.org/10.1148/radiol.2021210436.CrossRefPubMed

Title: Optimization of FDG PET study after mRNA COVID-19 vaccination to reduce the interference of vaccine-associated hypermetabolic lymphadenopathy
Author: Wajana Thaweerat
Publication date: 01-03-2022
Publisher: Springer Singapore
Keywords: COVID-19 Vaccination
Vaccination
Lymphadenopathy
Published in: Annals of Nuclear Medicine / Issue 3/2022
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-021-01712-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Optimization of FDG PET study after mRNA COVID-19 vaccination to reduce the interference of vaccine-associated hypermetabolic lymphadenopathy

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2022

Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo

I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response

A design of forceps-type coincidence radiation detector for intraoperative LN diagnosis: clinical impact estimated from LNs data of 20 esophageal cancer patients

Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab

An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma

Serial change in perfusion–metabolism mismatch after coronary artery bypass grafting